Why is Aardvark Therapeutics facing a securities class action lawsuit?

Investors allege Aardvark made misleading statements about ARD-101’s safety and overstated the drug candidate’s clinical, regulatory, and commercial prospects.

What are the allegations against Aardvark Therapeutics?

The complaint alleges Aardvark’s IPO documents and later public statements misrepresented or omitted material information about ARD-101’s safety and prospects.

What is the Aardvark Therapeutics IPO lawsuit about?

The lawsuit alleges Aardvark’s February 2025 IPO Offering Documents contained material misstatements or omissions concerning ARD-101 and its safety profile.

Why is ARD-101 important to the Aardvark Therapeutics lawsuit?

ARD-101 is a drug candidate central to the allegations. Plaintiffs claim it was less safe than investors were led to believe.

What are investors alleging about ARD-101’s safety?

The complaint alleges Aardvark failed to adequately disclose information showing ARD-101 was less safe than the Company had represented.

What did Aardvark Therapeutics allegedly fail to disclose?

Plaintiffs allege Aardvark failed to disclose material information about ARD-101’s safety and the resulting risks to its clinical, regulatory, and commercial prospects.

Were Aardvark Therapeutics’ IPO documents allegedly misleading?

Yes. The complaint alleges the Offering Documents contained material misstatements or omissions and were negligently prepared.

Why do drug safety disclosures matter to Aardvark investors?

Drug safety can affect clinical development, regulatory approval, commercialization, and a biotechnology company’s financial prospects.

How could ARD-101 safety concerns affect Aardvark Therapeutics?

Safety concerns may affect clinical development, regulatory review, commercialization prospects, and investor expectations for a drug candidate.

Who may qualify to participate in the Aardvark Therapeutics class action?

Investors who acquired Aardvark shares in its February 2025 IPO or securities between February 13, 2025 and May 14, 2026 may be eligible if they suffered losses.

What is the deadline to seek lead plaintiff status in the Aardvark lawsuit?

Eligible investors seeking appointment as lead plaintiff must file a motion with the court by October 13, 2026.

What is a securities class action lawsuit?

A securities class action allows investors to collectively pursue claims based on alleged material misstatements, misleading disclosures, or omissions.

What does the class period mean in a securities class action?

The class period identifies the timeframe during which the alleged misleading statements occurred and qualifying investors acquired securities.

What is a lead plaintiff in a securities class action?

A lead plaintiff is an investor appointed by the court to represent the proposed class and help oversee the litigation on behalf of class members.

Do investors need to become lead plaintiff to participate in a potential recovery?

No. Eligible investors generally do not need to serve as lead plaintiff to participate in a potential settlement or other recovery.

Aardvark Therapeutics, Inc. - Faruqi & Faruqi LLP

Aardvark Therapeutics, Inc.

Join Action

Case Details

Ticker AARD

Class Period 02/13/2025 - 05/14/2026

Lead Plaintiff Deadline 10/13/2026

Days Left to Seek Lead Plaintiff

If you are a Aardvark Therapeutics investor who suffered a loss and would like to learn more, you can provide your information below:

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Aardvark To Contact Him Directly To Discuss Their Options

If you purchased or acquired securities in (a) Aardvark common stock pursuant and/or traceable to the Offering Documents (defined below) issued in connection with the Company’s initial public offering conducted on or about February 13, 2025 (the “IPO” or “Offering”); and/or (b) Aardvark securities between February 13, 2025 and May 14, 2026, both dates inclusive (the “Class Period”) and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Aardvark Therapeutics, Inc. (“Aardvark” or the “Company”) (NASDAQ: AARD) and reminds investors of the October 13, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that the Offering Documents were negligently prepared and, as a result, contained untrue statements of material fact or omitted to state other facts necessary to make the statements made not misleading and were not prepared in accordance with the rules and regulations governing their preparation. Additionally, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operations, and prospects. Specifically, the Offering Documents and Defendants made false and/or misleading statements and/or failed to disclose that: (1) ARD-101 was less safe than Defendants had led investors to believe; (2) accordingly, ARD-101’s clinical, regulatory, and commercial prospects were overstated; and (3) as a result, Defendants’ public statements were materially false and misleading at all relevant times.

Lead Plaintiff Deadline: October 13, 2026

Call Partner Josh Wilson at 877-247-4292 or 212-983-9330 (Ext. 1310)
Or submit your information below to learn about your rights.

Join Action

Aardvark Therapeutics, Inc.

Monetary Losses ($) *

Website URL

First Name *

Last Name *

Telephone *

Email *

Street Address

City

State

Zip Code

Purchases

1	Purchases Options Price per Share Date # of Shares Principal Amount Amount Paid Series or Cusip # of Contracts Price per Contract Exercise Price Expiration Date
1	Purchases Options Price per Share Date # of Shares Principal Amount Amount Paid Series or Cusip # of Contracts Price per Contract Exercise Price Expiration Date

Add Row

Sales

1	Sales Options Price per Share Date # of Shares Principal Amount Amount Paid Series or Cusip # of Contracts Price per Contract Exercise Price Expiration Date
1	Sales Options Price per Share Date # of Shares Principal Amount Amount Paid Series or Cusip # of Contracts Price per Contract Exercise Price Expiration Date

Add Row

Upload your trades here:

Accepted file types: xls, xlsx, doc, docx, pdf, jpg, jpeg, png, Max. file size: 50 MB, Max. files: 5.
You may redact account numbers from your uploaded documents.

File name:

File size:

Select File

Does not establish an attorney-client relationship *

By clicking this box, I acknowledge that this form is not intended to and does not establish an attorney-client relationship between myself and Faruqi & Faruqi LLP, and that the submission or receipt of information via this form, e-mail or telephone does not create an attorney-client relationship.

Case

Users to notify